ACM
AMLX icon

Aquatic Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Aquatic Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$708K Buy
+39,425
New +$610K 0.02% 676
2026
Q1 		– Sell
-24,352
Closed -$294K – 1341
2025
Q4 		$294K Buy
+24,352
New +$331K 0.01% 896

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Aquatic Capital Management's AMLX Position: Q2 2026 in Review

Aquatic Capital Management opened a new position in Amylyx Pharmaceuticals (AMLX) in Q2 2026: 39,425 shares worth $708K. The stake represents 0.02% of the portfolio and ranks #676 among its holdings. This is a return to the name: Aquatic Capital Management previously reported a position in AMLX as recently as Q4 2025.

Aquatic Capital Management first reported a position in AMLX in Q4 2025 and has held it in 2 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Aquatic Capital Management held 39,425 shares of Amylyx Pharmaceuticals worth $708K as of Q2 2026.
  • Amylyx Pharmaceuticals was a new Aquatic Capital Management position in Q2 2026.
  • Amylyx Pharmaceuticals made up 0.02% of Aquatic Capital Management's portfolio in Q2 2026, its #676 holding.
  • Aquatic Capital Management first reported a position in Amylyx Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Aquatic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.